Alternative Splicing for Diseases, Cancers, Drugs, and Databases

Alternative splicing is a major diversification mechanism in the human transcriptome and proteome. Several diseases, including cancers, have been associated with dysregulation of alternative splicing. Thus, correcting alternative splicing may restore normal cell physiology in patients with these diseases. This paper summarizes several alternative splicing-related diseases, including cancers and their target genes. Since new cancer drugs often target spliceosomes, several clinical drugs and natural products or their synthesized derivatives were analyzed to determine their effects on alternative splicing. Other agents known to have modulating effects on alternative splicing during therapeutic treatment of cancer are also discussed. Several commonly used bioinformatics resources are also summarized.


Introduction to Alternative Splicing
Alternative splicing of RNA is a key mechanism of increasing complexity in mRNA and proteins [1]. Since alternative splicing apparently controls almost all human gene activities, imbalances in the this splicing process may affect the progression of various human diseases and cancers [2]. Varying alternations in excision and/or inclusion of exons may generate different mRNA transcripts and corresponding proteins. Therefore, in addition to mediating changes in protein structure, function, and localization [3], alternative splicing in higher eukaryotes affects the differentiation and development of cancer and other diseases [4].

Alternative Splicing and Diseases
Alternative RNA splicing is commonly reported in neurological and muscle diseases [5][6][7]. Studies show that these diseases at least partly result from alternative splicing, which regulates the complexity of integral membrane proteins, including changes in their topology, solubility, and signal peptides [3]. For example, aberrant alternative splicing has shown associations with Parkinson disease [3,8]. For spinal muscular atrophy (SMA), the level of survival motor neuron (SMN) protein was downregulated by its alternative splicing [9]. Therapies for SMA have recently improved by targeting RNA splicing for inclusion of exon 7 into SMN mRNA [10]. 2 The Scientific World Journal Phorbol 12-myristate 13-acetate was reported to modulate the alternative splicing of sarcoplasmic reticulum Ca 2+ -ATPase1 (SERCA1) which is dysregulated in myotonic dystrophy type 1 disease [11].
Single nucleotide polymorphisms (SNPs) affecting exon skipping has reviewed to confer to complex diseases [45]. The improvement of high-throughput technologies such as RNA-Seq [46,47] and exon arrays [48,49] is helpful to identify the genome-wide cancer-associated splicing variants. Splicing changes may associate with lung and prostate cancer risk in terms of some SNPs. For example, a coding synonymous SNP G870A of cyclin D1 (CCND1) with a modulating ability to its splice pattern was reported to be associated with lung cancer susceptibility [50]. Similarly, some coding synonymous SNPs may generate new splicing sites in the middle of an exon of p53 gene to change splicing [51]. Mutations in the adenomatous polyposis coli (APC) [52] and BRCA1 [53,54] genes have reported to skip exon by altering splicing. Furthermore, an intronic SNP, IVS −27 G>A/IVSΔA, creates a new splicing factor SR-binding site and deletes two other overlapping SRbinding sites, generating three alternative splicing forms of KLF6 (KLF6 SV1-3) [55]. This SNP was found to be associated with prostate cancer [56]. For lung cancer study, the tumor patients with overexpression of KLF6 SV1 have lower survival [56,57].
Actually, the information of many SNPs located in 3 and 5 splicing sites is searchable in the dbSNP in NCBI website (http://www.ncbi.nlm.nih.gov/snp) when the "limit" function is chosen. Researchers may choose the SNPs of splicing sites located in interested genes to identify their association relationships to diseases and cancers. A database consisting of genome-wide SNP and splicing sites, namely, ssSNPTarget [58] was designed to search the splice site SNPs (ssSNPs) by input of gene symbol, SNP rs number, transcript ID, or genomic position (http://variome.kobic.re.kr/ssSNPTarget/).

Alternative Splicing-Related Drugs and Natural Products
Splice modulating therapies have been developed for human disease [59][60][61] and cancer therapy [62,63]. Antitumor drugs have been developed to target alternative splicing [64], splice variants [65], and spliceosomes [66,67]. For example, pharmacological interventions may be affected by mRNA transcript diversity [68]. To correct aberrant splicing, specific mRNA transcripts have been targeted in genetic disorders such as Duchenne muscular dystrophy. Since mutations of splicing factor 3B subunit 1 (SF3B1) are common in several haematological malignancies, the use of various natural products and their synthetic derivatives in therapies targeting SF3B has proven highly effective [67]. For drug discovery for SMA, several small molecules including sodium vanadate [69], aclarubicin [70], and indoprofen [71], hydroxyurea [72], valproate [73], 5-(N-ethyl-Nisopropyl)-amiloride (EIPA) [74], and phenylbutyrate [75] that increases inclusion of exon 7 of SMN2 gene have been identified, although some of them may have side effects. Recently, novel phosphatase modulators, namely, pseudocantharidins have been discovered with the similar regulating function to SMN splicing [76]. Valproic acid was found to enhance SMN2 expression in SMA cell model involving the SF2/ASF and hnRNPA1 [77].
Clinical drugs such as novantrone (mitoxantrone) can enhance the effectiveness of therapeutic treatments for familial neurodegenerative diseases by stabilizing the tau pre-mRNA splicing regulatory element [78]. Tamoxifen has proven effective for clinical treatment of estrogen receptor-The Scientific World Journal 3 (ER-) positive breast cancer [79]. In endometrial cancer cells, alternative splicing of ER involving ER-alpha36 is also known to enhance the agonist activity of tamoxifen [80].
Natural products, including many xenobiotics, are also known to impair alternative splicing [81]. For example, natural products such as pladienolide B and FR901464 [82,83] are known to affect spliceosome function. However, the synthesis of these compounds is complicated by their multiple stereocenters. A recent study synthesized Sudemycins, which are novel analogues of FR901464. By inducing alternative gene splicing, the Sudemycins conferred both in vitro and in vivo antitumor effects [84]. Alternative splicing has also shown regulating effects on the antitumor drug Spliceostatin A, a stabilized derivative of a Pseudomonas bacterial fermentation product [85] which specifically targets the SF3b spliceosome subcomplex to inhibit pre-mRNA splicing [86]. Meayamycin, an analogue of the natural antitumor product FR901464 [87], inhibits RNA splicing against multidrug-resistant cells and performs antiproliferative effect against human breast cancer MCF-7 cells by suppression of alternative splicing [88]. These results suggest that, because of their modulating effects on RNA splicing, xenobiotic analogs have potential use as chemical probes and as anticancer agents. Similarly, the polyketide natural product borrelidin inhibits cancer metastasis by modulating alternative splicing in VEGF [89]. Antitumor effects involving alternative splicing [90,91] have also been reported in natural dietary products. For example, resveratrol can modulate exon inclusion of SRp20 and SMN2 pre-mRNAs and induce the expression of processing factors of alternative splicing such as ASF/SF2, hnRNPA1, and HuR [92].
Recent studies have investigated the role of splice variants in apoptotic pathways [93,94]. Regulation of alternative splicing genes may have anticancer effects. For example, BCL-X s and BCL-X L have been associated with proapoptotic and antiapoptotic effects, respectively, during the progression of cancer [67,95,96]. The ratio of BCL-X s /BCL-X L can be decreased by the treatment of protein kinase C (PKC) inhibitor and apoptotic inducer staurosporine in 293 cells [97]. Soluble and membrane-bound forms of TNF receptor superfamily, member 6 (FAS) containing exons 5/7 and 5/6/7 also display proapoptotic and antiapoptotic effects, respectively [67]. The caspase 9 (CASP9) gene has two antagonistic isoforms, proapoptotic Casp9a and prosurvival Casp9b, and its splicing is dysregulated in NSCLC lung cancer cell lines [98].
Alternative splicing is regulated by chromatin structure and histone modifications [4]. In thyroid tumor cells, for example, histone deacetylase inhibitors such as butyrate modulate transcription and alternative splicing of prohibitin [99]. A study of bovine epithelial cells showed that butyrate, a major metabolite generated by bacterial fermentation of dietary fiber in colon cells, has regulating effects on apoptosis and cell proliferation through alternative splicing [100]. Since histone deacetylase inhibitor may have antitumor effects, the identification of this kind of inhibitor in natural products can improve drug development for tumor therapy.

Alternative Splicing-Related Bioinformatics Resources
Several bioinformatics analyses for the detection and regulation of alternative splicing have been well reviewed [101][102][103]. However, these literatures mainly focused on the methodology for detection of alternative splicing, and the databases of alternative splicing are less addressed and summarized. Here, we collect several helpful bioinformatics resources related to alternative splicing as shown in Table 1.
For example, AsMamDB [104] is one of the early established alternative splice databases of mammals, although their websites are not functional currently. PALS db [105] provides the putative alternative splicing database based on UniGene clusters of human and mouse sources which mainly consist of EST data. Similarly, some databases such as EASED [107] and AVATAR [108] are constructed by datasets of EST and mRNAs. ASAP [106] provides the detail annotation for exon-intron boundary, alternative splicing, and its tissue specificity for the user to design probes for distinguishing different splicing isoforms. MAASE [109] is also specifically designed to apply in splicing microarray experiments. In contrast, Splicy [115] provide the web-based tool to predict possible alternative splicing events from Affymetrix probe set inputs. ASTALAVISTA [116] provides alternative splicing prediction for transcriptome data from GENCODE, REFSEQ, and ENSEMBL as well as from custom gene datasets. Furthermore, SpliceCenter [120] is a web server for predicting the influence of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based data.
Both PolyA DB [110] and AltTrans provide the information for alternative polyadenylation [111]. For AltTrans, the AltSplice pipeline on splicing and the AltPAS pipeline on polyadenylation were implemented. ASTD [126] also provides the variants for splicing, transcription initiation, and polyadenylation. Of note, the dataset of transcriptomics for alternative splicing is larger than for alternative polyadenylation. GRSDB [112] is a mammalian database of alternative splicing based on quadruplex forming G-rich sequences which modulate the 3 end processing of pre-mRNAs.
Additionally, several comprehensive databases for alternative splicing have been developed such as HOLLYWOOD [113], ASD [114], BIPASS [117], ECgene [118], ASPicDB [121], AspAlt [125], H-DBAS [128], SPLOOCE [129], and APPRIS [130]. For example, the ECgene provides EST and serial analysis of gene expression (SAGE) data-based annotation and visualization for alternative splicing (AS). The ASPicDB provides EST-based tissue-specific splicing information of normal and cancer cells. The H-DBAS provides alternative splicing annotation based on RNA-Seq transcriptomics data. The APPRIS provides the annotation for principal isoform as the standard reference sequence for each gene.
addressed. Some databases such as ProSAS [123] and SpliVaP [124] also provide the protein isoforms from the alternative splicing effects. In ProSAS, the protein isoforms of splicing transcripts are annotated in Ensembl or SwissProt. In SpliVap, protein signatures of alternative forms are annotated in terms of Pfam domains and PRINTS fingerprints.

Conclusion
Accumulating evidence shows that alternative splicing can be selectively targeted in several genes of cancer cells. An exciting possibility raised by this study is that the effectiveness of anticancer therapies may be enhanced by clinical drugs, natural products, and their synthesized analogs that target alternative splicing machinery. Some alternative splicingrelated databases and web servers may also helpful to improve the alternative splicing therapy for treating cancer and other diseases.